In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, CD
/ immunology
Antigens, Differentiation, Myelomonocytic
/ immunology
Biomarkers, Tumor
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Central Nervous System Neoplasms
/ immunology
Child
Female
Herpesvirus 4, Human
/ pathogenicity
Humans
Lymphocytes, Tumor-Infiltrating
/ immunology
Lymphoma
/ immunology
Male
Middle Aged
Receptors, Cell Surface
/ immunology
Retrospective Studies
T-Lymphocytes, Cytotoxic
/ immunology
Tumor Microenvironment
/ immunology
Young Adult
Immunotherapy
PCNSL
Primary central nervous system lymphoma
TILS
TME
Tumor microenvironment
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
28
11
2019
accepted:
10
04
2020
pubmed:
27
4
2020
medline:
18
8
2020
entrez:
27
4
2020
Statut:
ppublish
Résumé
Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma with an aggressive clinical course. To investigate the potential of immune-checkpoint therapy, we retrospectively studied the tumor microenvironment (TME) using high-plex immunohistochemistry in 22 PCNSL and compared to 7 secondary CNS lymphomas (SCNSL) and 7 "other" CNSL lymphomas with the presence of the Epstein-Barr virus and/or compromised immunity. The TME in PCNSL was predominantly composed of CD8+ cytotoxic T cells and CD163+ phagocytes. Despite molecular differences between PCNSL and SCNSL, the cellular composition and the functional spectrum of cytotoxic T cells were similar. But cytotoxic T cell activation was significantly influenced by pre-biopsy corticosteroids intake, tumor expression of PD-L1 and the presence of EBV. The presence of low numbers of CD8+ T cells and geographic-type necrosis each predicted inferior outcome in PCNSL. Both M1-like (CD68 + CD163
Identifiants
pubmed: 32335702
doi: 10.1007/s00262-020-02575-y
pii: 10.1007/s00262-020-02575-y
doi:
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
Biomarkers, Tumor
0
CD163 antigen
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1751-1766Subventions
Organisme : KU Leuven
ID : 3M040406
Organisme : KU Leuven
ID : OT14/101
Organisme : Universitaire Ziekenhuizen Leuven, KU Leuven
ID : RT0817
Commentaires et corrections
Type : ErratumIn
Références
Kluin PM, Deckert M, Ferry JA (2017) Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th. IARC, Lyon, pp 300–302
Montesinos-Rongen M, Siebert R, Deckert M (2009) Primary lymphoma of the central nervous system: just DLBCL or not? Blood 113:7–10. https://doi.org/10.1182/blood-2008-04-149005
doi: 10.1182/blood-2008-04-149005
pubmed: 18802010
Chang C, Lin C-H, Cheng A-L, Medeiros LJ, Chang K-C (2015) Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. Histopathology 67:625–635. https://doi.org/10.1111/his.12706
doi: 10.1111/his.12706
pubmed: 25829022
Marcelis L, Charlien B, De Zutter A, Biesemans P, Vandenberghe P, Verhoef G, Gheysens O, Sagaert X, Dierickx D, Tousseyn T (2018) Other immunomodulatory/suppressive lymphoproliferative diseases: a single-center series of 72 biopsy confirmed cases. Mod Pathol 31:1457–1469
doi: 10.1038/s41379-018-0054-2
Scott DW, Gascoyne RD (2014) The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 14:517–534. https://doi.org/10.1038/nrc3774
doi: 10.1038/nrc3774
pubmed: 25008267
Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O’Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K et al (2016) Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica 101:531–540. https://doi.org/10.3324/haematol.2015.139493
doi: 10.3324/haematol.2015.139493
pubmed: 27132279
pmcid: 5004369
Ponzoni M, Berger F, Clement C, Tinguely M, Jouvet A, Ferreri AJM, DellOro S, Terreni MR, Doglioni C, Weis J, Cerati M, Milani M, Iuzzolino P, Motta T, Carbone A, Pedrinis E, Sanchez J, Blay J-Y, Reni M, Conconi A, Bertoni F, Zucca E, Cavalli F, Borisch B, International Extranodal Lymphoma Study Group (2007) Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol 138:316–323. https://doi.org/10.1111/j.1365-2141.2007.06661.x
doi: 10.1111/j.1365-2141.2007.06661.x
pubmed: 17555470
Kumari N, Krishnani N, Rawat A, Agarwal V, Lal P (2009) Primary central nervous system lymphoma: prognostication as per international extranodal lymphoma study group score and reactive CD3 collar. J Postgrad Med 55:247–251. https://doi.org/10.4103/0022-3859.58926
doi: 10.4103/0022-3859.58926
pubmed: 20083869
Komohara Y, Horlad H, Ohnishi K, Ohta K, Makino K, Hondo H, Yamanaka R, Kajiwara K, Saito T, Kuratsu J, Takeya M (2011) M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop 51:93–99
doi: 10.3960/jslrt.51.93
He M, Zuo C, Wang J, Liu J, Jiao B, Zheng J, Cai Z (2013) Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma. Neuro Oncol 15:727–734. https://doi.org/10.1093/neuonc/not012
doi: 10.1093/neuonc/not012
pubmed: 23482670
pmcid: 3661096
Four M, Cacheux V, Tempier A, Platero D, Fabbro M, Marin G, Leventoux N, Rigau V, Costes-Martineau V, Szablewski V (2017) PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival. Hematol Oncol 35:487–496. https://doi.org/10.1002/hon.2375
doi: 10.1002/hon.2375
pubmed: 27966264
Sasayama T, Tanaka K, Mizowaki T, Nagashima H, Nakamizo S, Tanaka H, Nishihara M, Mizukawa K, Hirose T, Itoh T, Kohmura E (2016) Tumor-associated macrophages associate with cerebrospinal fluid interleukin-10 and survival in primary central nervous system lymphoma (PCNSL). Brain Pathol 26:479–487. https://doi.org/10.1111/bpa.12318
doi: 10.1111/bpa.12318
pubmed: 26314692
Cho H, Kim S-JSH, Kim S-JSH, Chang JH, Yang WI, Suh C-O, Cheong J-W, Kim YR, Lee JY, Jang JE, Kim YR, Min YH, Kim JS (2017) The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma. Ann Hematol 96:1163–1173. https://doi.org/10.1007/s00277-017-3014-x
doi: 10.1007/s00277-017-3014-x
pubmed: 28508176
Cho H, Kim SH, Kim S-J, Chang JH, Yang W-I, Suh C-O, Kim YR, Jang JE, Cheong J-W, Min YH, Kim JS (2017) Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. Oncotarget 8:87317–87328. https://doi.org/10.18632/oncotarget.20264
doi: 10.18632/oncotarget.20264
pubmed: 29152083
pmcid: 5675635
Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869–881. https://doi.org/10.1182/blood-2015-10-673236
doi: 10.1182/blood-2015-10-673236
pubmed: 26702065
pmcid: 4760091
Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA (2017) PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 129:3071–3073. https://doi.org/10.1182/blood-2017-01-764209
doi: 10.1182/blood-2017-01-764209
pubmed: 28356247
pmcid: 5766844
Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133–150. https://doi.org/10.1038/s41568-019-0116-x
doi: 10.1038/s41568-019-0116-x
pubmed: 6705396
pmcid: 6705396
Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321–330. https://doi.org/10.1038/nature21349
doi: 10.1038/nature21349
pubmed: 28102259
pmcid: 28102259
Bosisio FM, Antoranz A, van Herck Y, Bolognesi MM, Marcelis L, Chinello C, Wouters J, Magni F, Alexopoulos L, Stas M, Boecxstaens V, Bechter O, Cattoretti G, van den Oord J (2020) Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing. Elife 9:1–28. https://doi.org/10.7554/elife.53008
doi: 10.7554/elife.53008
Miyasato Y, Takashima Y, Takeya H, Yano H, Hayano A, Nakagawa T, Makino K, Takeya M, Yamanaka R, Komohara Y (2018) The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma. J Clin Exp Hematop 58:95–101. https://doi.org/10.3960/jslrt.18001
doi: 10.3960/jslrt.18001
pubmed: 29998979
pmcid: 6413151
Illerhaus G, Schorb E, Kasenda B (2018) Novel agents for primary central nervous system lymphoma: evidence and perspectives. Blood 132:681–688. https://doi.org/10.1182/blood-2018-01-791558
doi: 10.1182/blood-2018-01-791558
pubmed: 29986908
Bolognesi MM, Manzoni M, Scalia CR, Zannella S, Bosisio FM, Faretta M, Cattoretti G (2017) Multiplex staining by sequential immunostaining and antibody removal on routine tissue sections. J Histochem Cytochem 65:431–444. https://doi.org/10.1369/0022155417719419
doi: 10.1369/0022155417719419
pubmed: 28692376
pmcid: 5533273
Cattoretti G, Cattoretti G, Bosisio FM, Marcelis L, Bolognesi MM (2018) Multiple iteractive labeling by antibody neodeposition (MILAN). Protoc Exch. https://doi.org/10.1038/protex.2018.106
doi: 10.1038/protex.2018.106
Morscio J, Dierickx D, Ferreiro JF, Herreman A, Van Loo P, Bittoun E, Verhoef G, Matthys P, Cools J, Wlodarska I, De Wolf-Peeters C, Sagaert X, Tousseyn T (2013) Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant 13:1305–1316. https://doi.org/10.1111/ajt.12196
doi: 10.1111/ajt.12196
pubmed: 23489474
Bankhead P, Loughrey MB, Fernández JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA, Salto-Tellez M, Hamilton PW (2017) QuPath: open source software for digital pathology image analysis. Sci Rep 7:16878. https://doi.org/10.1038/s41598-017-17204-5
doi: 10.1038/s41598-017-17204-5
pubmed: 29203879
pmcid: 5715110
Blaker YN, Spetalen S, Brodtkorb M, Lingjærde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB (2016) The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br J Haematol 175:102–114. https://doi.org/10.1111/bjh.14201
doi: 10.1111/bjh.14201
pubmed: 27341313
Gomez-Gelvez JC, Salama ME, Perkins SL, Leavitt M, Inamdar KV (2016) Prognostic impact of tumor microenvironment in diffuse large B-cell lymphoma uniformly treated with R-CHOP chemotherapy. Am J Clin Pathol 145:514–523. https://doi.org/10.1093/AJCP/AQW034
doi: 10.1093/AJCP/AQW034
pubmed: 27124945
Camilleri-Broët S, Criniè E, Broët P, Delwail V, Mokhtari K, Moreau A, Kujas M, Raphaël M, Iraqi W, Sautès-Fridman C, Colombat P, Hoang-Xuan K, Martin A (2006) Auniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190–196. https://doi.org/10.1182/blood-2005-03-1024
doi: 10.1182/blood-2005-03-1024
pubmed: 16150948
Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, Khodadoust MS, Esfahani MS, Luca BA, Steiner D, Diehn M, Alizadeh AA (2019) Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol 37:773–782. https://doi.org/10.1038/s41587-019-0114-2
doi: 10.1038/s41587-019-0114-2
pubmed: 31061481
pmcid: 31061481
Marcelis L, Tousseyn T (2019) The tumor microenvironment in post-transplant lymphoproliferative disorders. Cancer Microenviron 12:3–16. https://doi.org/10.1007/s12307-018-00219-5
doi: 10.1007/s12307-018-00219-5
pubmed: 30680693
pmcid: 6529504
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523:337–341. https://doi.org/10.1038/nature14432
doi: 10.1038/nature14432
pubmed: 26030524
pmcid: 26030524
Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212:991–999. https://doi.org/10.1084/jem.20142290
doi: 10.1084/jem.20142290
pubmed: 26077718
pmcid: 4493418
Grywalska E, Pasiarski M, Góźdź S, Roliński J (2018) Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. Onco Targets Ther 11:6505–6524. https://doi.org/10.2147/OTT.S150817
doi: 10.2147/OTT.S150817
pubmed: 30323625
pmcid: 6177399
Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K (2018) Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer 17:129. https://doi.org/10.1186/s12943-018-0864-3
doi: 10.1186/s12943-018-0864-3
pubmed: 30139382
pmcid: 30139382
Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié J-J, Laurent C (2017) Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget 8:44960–44975. https://doi.org/10.18632/oncotarget.16680
doi: 10.18632/oncotarget.16680
pubmed: 28402953
pmcid: 5546533
Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D’Andrea MR, Bihun I, Kaneb A, Dietrich J, Ferry JA, Martinez-Lage M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, Frosch MP, Batchelor E, Hoang K, Kuter B, Fortin S, Holdhoff M, Cahill DP, Carter S, Brastianos PK, Batchelor TT (2019) MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv 3:375–383. https://doi.org/10.1182/bloodadvances.2018027672
doi: 10.1182/bloodadvances.2018027672
pubmed: 30723112
pmcid: 6373750
Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R (2018) Role of PD-1 during effector CD8 T cell differentiation. Proc Natl Acad Sci USA 115:4749–4754. https://doi.org/10.1073/pnas.1718217115
doi: 10.1073/pnas.1718217115
pubmed: 29654146
Mita Y, Kimura MY, Hayashizaki K, Koyama-Nasu R, Ito T, Motohashi S, Okamoto Y, Nakayama T (2018) Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells. Int Immunol 30:559–567. https://doi.org/10.1093/intimm/dxy050
doi: 10.1093/intimm/dxy050
pubmed: 30085193
Kamper P, Bendix K, Hamilton-Dutoit S, Honoré B, Nyengaard JR et al (2011) Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein–Barr virus status in classical Hodgkin’s lymphoma. Haematologica 96:269–276. https://doi.org/10.3324/haematol.2010.031542
doi: 10.3324/haematol.2010.031542
pubmed: 21071500
Quaranta V, Schmid MC (2019) Macrophage-mediated subversion of anti-tumour immunity. Cells 8:747. https://doi.org/10.3390/cells8070747
doi: 10.3390/cells8070747
pmcid: 6678757
He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch FR (2018) TIM-3, a promising target for cancer immunotherapy. Onco Targets Ther 11:7005–7009. https://doi.org/10.2147/OTT.S170385
doi: 10.2147/OTT.S170385
pubmed: 6198883
pmcid: 6198883
Stelling A, Hashwah H, Bertram K, Manz MG, Tzankov A, Müller A (2018) The tumor suppressive TGF-b/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood 131:2235–2246. https://doi.org/10.1182/blood-2017-10-810630
doi: 10.1182/blood-2017-10-810630
pubmed: 29615404
Batlle E, Massagué J (2019) Transforming growth factor-β signaling in immunity and cancer. Immunity 50:924–940. https://doi.org/10.1016/j.immuni.2019.03.024
doi: 10.1016/j.immuni.2019.03.024
pubmed: 30995507
pmcid: 30995507
Zöller T, Schneider A, Kleimeyer C, Masuda T, Potru PS, Pfeifer D, Blank T, Prinz M, Spittau B (2018) Silencing of TGFβ signalling in microglia results in impaired homeostasis. Nat Commun 9:1–13. https://doi.org/10.1038/s41467-018-06224-y
doi: 10.1038/s41467-018-06224-y
Dierickx D, Tousseyn T, Verhoef G, Moyer A (2010) Primary central nervous system post-transplatation lymphoproliferative disorder. Cancer 116:3521. https://doi.org/10.1002/cncr.25340
doi: 10.1002/cncr.25340
pubmed: 20564159